GNPX - Genprex, Inc.

1.155
-0.145   -12.554%

Share volume: 969,522
Last Updated: 04-20-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.17%

PREVIOUS CLOSE
CHG
CHG%
$1.30
-0.15
-0.11%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
18%
Profitability 25%
Dept financing 3%
Liquidity 75%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-11.15%
1 Month
-39.53%
3 Months
-59.19%
6 Months
-89.96%
1 Year
413.11%
2 Year
-46.60%
Key data
Stock price
$1.16
P/E Ratio 
0.00
DAY RANGE
$1.15 - $1.30
EPS 
-$6.66
52 WEEK RANGE
$0.14 - $12.97
52 WEEK CHANGE
$411.74
MARKET CAP 
5.669 M
YIELD 
N/A
SHARES OUTSTANDING 
2.270 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-13-2025
BETA 
-3.92
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$494,430
AVERAGE 30 VOLUME 
$384,842
Company detail
CEO: J. Rodney Varner
Region: US
Website: genprex.com
Employees: 20
IPO year: 2018
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes.

Recent news